998P - An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Surgery and/or Radiotherapy of Cancer
Presenter Pongwut Danchaivijitr
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors P. Danchaivijitr1, N. Ngamphaiboon2, C. Jiarpinitnun3, E. Sirachainan4, P. Pattaranutaporn3, J. Setakornnukul5
  • 1Medical Oncology Division, Department Of Medicine, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH
  • 2Division Of Medical Oncology, Department Of Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 3Radiation Oncology, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 4Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 5Radiation Oncology, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH

Abstract

Background

To date, there is no recommended optimal cumulative dose (OCD) of cisplatin in definitive chemoradiotherapy (CRT) for non-metastatic nasopharyngeal carcinoma (NPC). We conducted a retrospective study to determine a MCCD in NPC treated with CRT.

Methods

Histologically confirmed non-metastatic NPC patients treated at the Ramathibodi and Siriraj Hospitals between 2007 and 2015 were identified. Baseline patient characteristics, treatment modality and survivals were abstracted. The OCD of cisplatin >200 mg/m2 was used as a stratification dose level. Primary end point was 3-year survival (OS). The Kaplan-Meier with log-rank test were used for analysis. A p-value

Results

Total of 289 NPC patients were included for analysis. Two hundred and thirty one patients received OCD of cisplatin >200 mg/m2, while 58 patients did not. Median age was 52 (range 17-75). Median radiation dose was 6996 cGY (range 1440-7840). Median cisplatin dose was 240 mg/m2 (range 75-361). There was no statistical difference in demographics between these 2 groups, except radiation interruption was more common in patients who received ODC of cisplatin >200 mg/m2 (27% vs 3%, p 

Conclusions

Our study demonstrated no significant difference in 3 year OS and DFS between OCD of cisplatin greater or lesser than 200 mg/m2. A prospective study comparing standard vs lower dose of cisplatin is warranted to minimize cisplatin related toxicity during chemoradiotherapy for NPC.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.